Precigen's PAPZIMEOS, the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP), demonstrated durable complete responses in 83% of patients over at least 36 months without additional treatment. Five patients maintained responses beyond four years, with no new safety issues reported. The US FDA granted PAPZIMEOS a seven-year orphan drug market exclusivity, reinforcing its role as a new standard of care for this rare, debilitating disease. Ongoing follow-up continues to assess long-term efficacy and safety.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 results for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, combined with chemotherapy in untreated advanced non-small cell lung cancer (NSCLC). The ROSETTA Lung-02 trial s...
Computer engineer CharuSan argues XRP's potential $300 price is driven by integration into global banking infrastructure, not retail speculation. After regulatory clarity, XRP could be adopted system-wide via platforms like Volante Technologies, enab...
Hyperliquid (HYPE) surged past $67, reaching new all-time highs as strong buyer demand absorbed supply despite profit-taking by early investors. One major holder realized about $95 million in gains but still controls significant tokens, limiting supp...
ImPact Biotech presented updated positive data from its Phase 1 trial for Padeliporfin VTP in locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) and Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (LG-UTUC) at ASCO 2026...
